Physician profile
Ronald Pyram
NPI 1720241284
$11,926.49
in general payments reported to CMS, 2019-2025
23 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,641 · 2020: $27.92 · 2021: $734 · 2022: $754 · 2023: $149 · 2024: $203 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,966.33 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $758.49 | 2019-2024 | Lokelma |
| Novo Nordisk INC | $652.39 | 2019-2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $424.71 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $402.36 | 2021-2025 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.88 | 2019-2024 | Jardiance |
| Medtronic, INC. | $311.41 | 2021-2025 | Minimed 780g |
| Opko Pharmaceuticals, LLC | $222.97 | 2021-2022 | |
| Mannkind Corporation | $125.00 | 2019 | |
| Esperion Therapeutics, INC. | $124.45 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.35 | 2022 | |
| Tandem Diabetes Care, INC. | $106.51 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $91.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.35 | 2019 | |
| Shire North American Group INC | $54.99 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $44.44 | 2019 | |
| Medtronic Minimed, INC. | $27.92 | 2020 | |
| Eisai INC. | $23.55 | 2019 | |
| Gilead Sciences, INC. | $22.68 | 2019 | |
| Sanofi Pasteur INC. | $21.12 | 2019 | |
| Lilly USA, LLC | $15.67 | 2019 | |
| Corcept Therapeutics | $15.51 | 2019 | |
| Abbott Laboratories | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Pyram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.